
Medicine and Health
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
F. Ren, A. Aliper, et al.
This groundbreaking research identifies TRAF2-and NCK-interacting kinase (TNIK) as an anti-fibrotic target for idiopathic pulmonary fibrosis (IPF). Utilizing artificial intelligence, the study introduces INS018_055, a small-molecule TNIK inhibitor that demonstrates significant anti-fibrotic and anti-inflammatory effects in vivo. With successful Phase I clinical trials confirming safety and tolerability, this work by esteemed authors paves the way for AI-driven advancements in drug discovery.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.